Evidence map›Paper›PMID 30804994›Full record

ArticleGastroenterology research and practice2019

A Proposal of a Personalized Surveillance Strategy for Gastric Cancer: A Retrospective Analysis of 9191 Patients.

Si-Wei Pan, Peng-Liang Wang, Han-Wei Huang, Lei Luo, Xin Wang, Tao Wang, Fu-Nan Liu, Hui-Mian Xu

Abstract read
In one paragraph

Article in Gastroenterology research and practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Si-Wei PanDepartment of Surgical Oncology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.ORCID 0000-0002-8027-9341
Peng-Liang WangDepartment of Surgical Oncology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Han-Wei HuangDepartment of Surgical Oncology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Lei LuoDepartment of Surgical Oncology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Xin WangDepartment of Surgical Oncology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Tao WangDepartment of Surgical Oncology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.
Fu-Nan LiuDepartment of Surgical Oncology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.ORCID 0000-0001-9889-2892
Hui-Mian XuDepartment of Surgical Oncology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China.ORCID 0000-0002-1177-4445

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn gastric cancer, various surveillance strategies are suggested in international guidelines. The current study is intended to evaluate the current strategies and provide more personalized proposals for personalized cancer medicine. MATERIALS AND

methodsIn the aggregate, 9191 patients with gastric cancer after gastrectomy from 1998 to 2009 were selected from the Surveillance, Epidemiology, and End Results database. Disease-specific survival was analyzed by Kaplan-Meier method and the log-rank test. Cox proportional hazards regression analyses were used to confirm the independent prognostic factors. As well, hazard ratio (HR) curves were used to compare the risk of death over time. Conditional survival (CS) was applied to dynamically assess the prognosis after each follow-up.

resultsComparisons from HR curves on different stages showed that earlier stages had distinctly lower HR than advanced stages. The curve of stage IIA was flat and more likely the same as that of stage I while that of stage IIB is like that of stage III with an obvious peak. After estimating CS at intervals of three months, six months, and 12 months in different periods, stages I and IIA had high levels of CS all along, while there were visible differences among CS levels of stages IIB and III.

conclusionsThe frequency of follow-up for early stages, like stages I and IIA, could be every six months or longer in the first three years and annually thereafter. And those with unfavorable conditions, such as stages IIB and III, could be followed up much more frequently and sufficiently than usual.

Identifiers

PMID30804994
PMCPMC6362503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.